Cost-benefit analysis of serological and nucleic acid testing for hepatitis B virus in blood donors in southern China
Universal HBsAg ELISA screening in combination with HBV ID NAT or MP-6 NAT strategies was highly cost effective in China. To further improve blood safety, HBsAg plus HBV DNA ID NAT screening should be considered in HBV endemic regions/countries.
Authors
- Limin Chen (ORCID: https://orcid.org/0000-0003-4937-2756)
- Wen Xiong (ORCID: https://orcid.org/0000-0003-0217-2992)
- Xianlin Ye
- Baoren He (ORCID: https://orcid.org/0000-0001-6377-1919)
- Jinfeng Zeng (ORCID: https://orcid.org/0000-0001-6140-8040)
- Bin Li (ORCID: https://orcid.org/0000-0003-2945-4092)
- He Xie (ORCID: https://orcid.org/0000-0002-4123-7683)
- Xiaoxuan Xu (ORCID: https://orcid.org/0000-0003-2223-5778)
- Qiuhong Mo
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Guangzhou Blood Center (CN)
- China XD Group (China) (CN)
- Shenzhen Blood Center (CN)
Publication Details
- Journal
- BMC Infectious Diseases
- Published
- 2024-09-02
- DOI
- https://doi.org/10.1186/s12879-024-09786-z
- Citations
- 5
- Primary Topic
- Hepatitis B Virus Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.93
Funders
- Xi'an Municipal Bureau of Science and Technology
- National Key Research and Development Program of China
- Chinese Academy of Medical Sciences Initiative for Innovative Medicine